Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
34 hedge funds and large institutions have $6.51M invested in Checkpoint Therapeutics in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 5 reducing their positions, and 8 closing their positions.
160% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 5
94% more call options, than puts
Call options by funds: $248K | Put options by funds: $128K
73% more capital invested
Capital invested by funds: $3.76M → $6.51M (+$2.75M)
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
0% more funds holding
Funds holding: 34 → 34 (0)
6.26% less ownership
Funds ownership: 23.92% → 17.66% (-6.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.86M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$156K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$153K |
| 4 |
LWAM
Legacy Wealth Asset Management
Woodbury,
Minnesota
|
+$113K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$72.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAG
Spotlight Asset Group
Oakbrook Terrace,
Illinois
|
-$622K |
| 2 |
CAC
Cowen and Company
New York
|
-$495K |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$328K |
| 4 |
PAM
PVG Asset Management
Golden,
Colorado
|
-$208K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$34K |
CKPT Hedge Fund Activity: Q2 2023 in Review
34 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q2 2023, worth a combined $6.51M — up 73% from $3.76M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CKPT positions and 8 closed out — a net gain of 1 holder — while 13 added to existing stakes and 5 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.86M. The largest seller was Spotlight Asset Group, exiting entirely with an estimated $622K sold.
- 34 institutional investors held Checkpoint Therapeutics (CKPT) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $6.51M of Checkpoint Therapeutics stock for Q2 2023, up 73% quarter-over-quarter.
- 9 funds opened new Checkpoint Therapeutics positions in Q2 2023 and 8 closed out, a net change of +1 holder.
- The largest Checkpoint Therapeutics buyer in Q2 2023 was Armistice Capital, an estimated $3.86M added.
- The largest Checkpoint Therapeutics seller in Q2 2023 was Spotlight Asset Group, an estimated $622K sold.
Based on aggregated 13F filings for Q2 2023.